Endometrial Cancer Trial, Recruiting NCT05749887 Sponsor: Chongqing University Cancer Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05749887
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with cervical cancer at a specific stage (Stage Ib3, IIA2, IIB, III, or IVA using the FIGO 2018 staging system), with one of three specific cancer cell types: squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma.
  • People who have completed a full standard course of combined radiation and chemotherapy treatment, including internal radiation (brachytherapy) and platinum-based chemotherapy given at the same time as external radiation.
  • People whose treatment finished 4 to 12 weeks ago, and where either a cervical biopsy confirmed cancer is still present, or a PET/CT scan showed signs of remaining disease in the cervix or nearby lymph nodes meeting specific scan measurement criteria — and where a specialist medical team has recommended surgery as the next step.
  • People with a physical fitness score of 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity — confirm with trial site).
  • People whose life expectancy is estimated to be more than 6 months.
  • People who have no absolute medical reason preventing surgery and who are able to follow the trial requirements.

Who may not be able to join:

  • People who did not complete their full course of radiation and chemotherapy, or who did not receive the required radiation dose.
  • People whose PET/CT scan or biopsy results show cancer has spread to distant parts of the body, including lymph nodes near the main abdominal artery (para-aortic lymph nodes).
  • People who have been diagnosed with another cancer within the past five years, or who are currently being treated for another cancer.
  • People who have had a major organ transplant.
  • People with an immune system disease that requires them to take medication to suppress the immune system.
  • People with a history of serious mental illness or significant brain function disorder.
  • People with a history of drug abuse or substance misuse.
  • People who are currently participating in another clinical trial at the same time.
  • People who are unable or unwilling to have surgery, sign a consent form, or follow the study requirements.
  • People who have certain serious medical conditions affecting the kidneys, liver, lungs, or heart that make surgery unsafe (confirm specific details with the trial site).
  • People who are unable to understand the study plan or who decline to sign the informed consent form.
  • People with other serious illnesses or conditions that could significantly affect their health or interfere with the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dongling Zou, PH.D, Chongqing University Cancer Hospital

Phone: 13657690699

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chongqing University Cancer Hospital
Registry
ClinicalTrials.gov
Start date
25 August 2023
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

OS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov